<qa>  How many first hemorrhagic stroke patients will be randomly divided into the control andThis will be a double-blind, randomized, placebo-controlled study. An estimated 60 at least 48 evaluable first hemorrhagic stroke patients will be randomly divided into the control and treatment groups. Each group will be treated as follows: 1 control group will accept placebo t.i.w treatment for 14 days from second day of admission, in addition to standard ordinary treatment.; 2 treatment group will accept PG2 t.i.w treatment for 14 days from second day of admission, in addition to standard ordinary treatment. Inflammatory index including the levels of C-Reactive Protein CRP, Erythrocyte Sedimentation Rate ESR, S-100 protein, IL-1, IL-6, and TNF-beta levels will be measured and clinical symptoms including Glasgow outcome scale GOS, modified rankin scale MRS, Functional Independence Measure FIM and Barthel Index BI will be evaluated during this study. 